We aim to complete the development, testing and introduction of the worlds first long term implantable micro sensor to give people with diabetes the modern tool they deserve for monitoring glucose levels.
Detecting glucose by the principle of the osmotic pressure holds promise of a glucose sensing technology that is suitable for both miniaturization and long term continuous monitoring in vivo without causing patient discomfort or reducing quality of life. It also offers several major advantages compared to current blood glucose measurement technologies.
Our headquarter is located in Bergen, Norway. The research and development is performed through our research partner across Europe.
Lifecare AS (Ltd.) is listed on Oslo Stock Exchange (LIFE-ME), and has been dedicated to the research and development of medical sensors for health monitoring since 06/07.
The Sencell-technology is protected by patents owned by Lifecare AS (LIFE-ME). These patents are granted until year 2030 and new patents are pending.
Proof of concept of the proprietary osmotic pressure sensing technology has been successfully performed in two preclinical trials 2016 – 2017, proving that the pressure technology is able to track interstitial glucose and providing stable references.
Further miniaturization of the injectable glucose sensor highlights the planned device evolution and the accuracy of the employed 3D nanosensor technology measurement system. Data shows that the Sencell technology probably employs the smallest MEMS based pressure sensor in the world, with a reliable reproducibility of measurement results and a pressure resolution, which should lead to a resolution of glucose differences higher than CGM-devices currently on the market.
Lifecare is now continuing the development of a wireless sensor prototype suitable for first long term human clinical.
Kronstad is a partner in the law firm Schjødt and has extensive experience as a business lawyer with main areas of work in M&A and corporate, including corporate litigation. He serves on a number of boards as chairman and board member in Norwegian listed and un-listed companies.
Heinemann has a broad academic background with a special focus on research and development in insulin pharmacology and diabetes technology. Heinemann established the Profil Institute for Metabolic Research in Neuss, Germany in 2009 and since 2011 he has been Managing Editor of The Journal of Diabetes Science and Technology.
Peterson holds a Ph.D. in Chemistry from The Technical University of Denmark. Peterson has over 20 years of work experience in developing diabetes technology products, most recently as Head of Diabetes Care at Cambridge Consultants, Cambridge, UK. Petersson is today also engaged as Chief Scientific Officer in RSP Systems A / S, Copenhagen, Denmark.
Hekland has a master's degree in economics from the Norwegian School of Management (Siviløkonom -NHH). He has worked as Managing Partner in Sarsia Venture Management since 2001.
Hekland has broad expertise in fund management, strategy, business development and finance. He has extensive experience from board positions and involvement in the medical development companies and other listed and unlisted companies.
The research and development is performed through our research partner across Europe. Our partners are all rated global experts in their field.
We take our role in developing the next generation of diagnostics healthcare platform and sensor solutions seriously.
Digid is engaged in several research projects involving excellent international research partners as well as well-established technology providers.digid is developing a new kind of diagnostics healthcare platform solution through a proprietary combination of sensorics, biotech, A.I. and software that will, for the first time enable real-time identification of different biomarkers.
At the very core of digid ´s development, is a proprietary biosensor in combination with specifically designed receptors and digid´s Healthtech App as well as a fully integrated, A.I. powered Data Platform for real-time diagnostics of multiple human biomarkers.
This custom, real-time diagnostics procedure enables the identification of multiple human biomarkers in real-time and gives users / patients personalized recommendations on how to improve the current state of wellbeing. This can be a recommended doctor visit with a subsequent therapeutical treatment, specific nutritional supplements or other personalized recommendations to improve wellbeing and the current health-state
Visit website
Research at the University of Bath is improving lives and changing the world we live in.
Ranked 6th in the UK by the Guardian University Guide 2020
Awarded Gold in the Teaching Excellence Framework 2017
87% of our research is classed as world-leading or internationally excellent by the most recent Research Excellence Framework 2014
PFÜTZNER Science & Health Institute deliver research at the highest level, incl
Centre for clinical studies (phases II – IV)
Centre for medicinal/medical product studies (incl. CE studies)
Laboratory studies pursuant to ISO15197:2013 for blood glucose monitoring systems
Performance/preference studies for medical products
Strategy and performance of clinical investigations
